Savara to Present Phase 3 IMPALA-2 Clinical Trial Data for Rare Lung Disease Drug at CHEST 2026

Savara Inc. (NASDAQ:SVRA) will present updated clinical trial data for its lead drug candidate, molgramostim, at the CHEST 2026 annual meeting in Phoenix, Arizona, from October 18 to October 21, 2026. The biopharmaceutical company received acceptance for an encore oral presentation covering long-term efficacy and safety results from the Phase 3 IMPALA-2 study, alongside a poster presentation on Phase 2/3 IMPALA trial data. Shares of Savara closed down 1.52% at $4.845 following the announcement.

Molgramostim is an inhaled therapy designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare condition where buildup of surfactant in the lungs leads to shortness of breath, coughing, and potential severe complications like lung fibrosis. The upcoming presentations will highlight long-term treatment outcomes and patient responses in individuals with mild diffusion impairment, offering further context on the therapy's safety and clinical profile.

Investors and healthcare providers will evaluate the detailed clinical findings delivered during the conference sessions scheduled for October 20 and October 21, 2026. Key updates will focus on open-label treatment outcomes and disease management insights for aPAP patients.